In the management of dyslipidemia, it is believed that drug prescriptions will be more aggressive in Korea. In April, The Korean Society of Lipid and Atherosclerosis unveiled some of the contents of the fifth edition of the 2022 dyslipidemia treatment guidelines at the Spring Conference, and will officially announce it in September. What is noteworthy in the new guidelines is that patients with Chronic kidney disease stage 1-3 are considered to be at high risk, and a reduction in low-density lipoprotein cholesterol (LDL-C) is recommended as a basic treatment goal.

In 2017, the American Association of Clinical Endocrinologists (AACE) established an extreme risk for cardiovascular disease and recommended